ABSTRACT

In this study, it was aimed to compare the changes in antibiotic resistance profiles in Acinetobacter baummannii and Pseudomonas aeruginosa isolates between the pre-pandemisc and pandemics periods. A total of 87 Gram negative non-fermentary bacteria strains (53 Acinetobacter baummannii and 34 Pseudomonas aeruginosa) isolated from the tracheal aspirates of intensive care unit patients in 2018 and 2019 were included in the study as the pre-pandemics group. And a total of 69 strains (38 A. baumannii and 31 P. aeruginosa) isolated in 2021 and 2022 were enrolled as the pandemic strains. It was determined that the resistance rates of imipenem (p=0.001), amikacin (p=0.001), tobramycin (p=0.001), levofloxacin (p=0.015) and piperacillin-tazobactam (p=0.037) in Acinetobacter isolates increased significantly during the pandemic period compared to the pre-pandemic period. It was determined that the resistance rates of imipenem (p=0.029), amikacin (p=0.037), tobramycin (p=0.034), levofloxacin (p=0.037) and piperacillin-tazobactam (p=0.036) in Pseudomonas isolates increased significantly during the pandemic period compared to the pre-pandemic period. In conclusion, the findings from our study showed that there was a significant increase in antibiotic resistance in Acinetobacter and Pseudomonas isolates with the pandemic and that the pandemic had a reducing effect on treatment alternatives.

Keywords

COVID-19, resistance, Acinetobacter.

MJE-004